These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1454066)

  • 1. Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1.
    Dorai H; Wesolowski JS; Gillies SD
    Mol Immunol; 1992 Dec; 29(12):1487-91. PubMed ID: 1454066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis.
    Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
    Mol Immunol; 1993 Nov; 30(16):1419-25. PubMed ID: 8232327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds.
    Schuurman J; Perdok GJ; Gorter AD; Aalberse RC
    Mol Immunol; 2001 Jan; 38(1):1-8. PubMed ID: 11483205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrachain disulfide bond in the core hinge region of human IgG4.
    Bloom JW; Madanat MS; Marriott D; Wong T; Chan SY
    Protein Sci; 1997 Feb; 6(2):407-15. PubMed ID: 9041643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture.
    Heads JT; Adams R; D'Hooghe LE; Page MJ; Humphreys DP; Popplewell AG; Lawson AD; Henry AJ
    Protein Sci; 2012 Sep; 21(9):1315-22. PubMed ID: 22761163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetically engineered human IgG mutant with enhanced cytolytic activity.
    Shopes B
    J Immunol; 1992 May; 148(9):2918-22. PubMed ID: 1573276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement.
    Shopes B
    Mol Immunol; 1993 Apr; 30(6):603-9. PubMed ID: 8487779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.
    Michaelsen TE; Brekke OH; Aase A; Sandin RH; Bremnes B; Sandlie I
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9243-7. PubMed ID: 7937748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.
    Shen Y; Zeng L; Zhu A; Blanc T; Patel D; Pennello A; Bari A; Ng S; Persaud K; Kang YK; Balderes P; Surguladze D; Hindi S; Zhou Q; Ludwig DL; Snavely M
    MAbs; 2013; 5(3):418-31. PubMed ID: 23567210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody.
    Angal S; King DJ; Bodmer MW; Turner A; Lawson AD; Roberts G; Pedley B; Adair JR
    Mol Immunol; 1993 Jan; 30(1):105-8. PubMed ID: 8417368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function.
    Dorai H; Mueller BM; Reisfeld RA; Gillies SD
    Hybridoma; 1991 Apr; 10(2):211-7. PubMed ID: 1874515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic insights into inter-chain disulfide bond reduction of IgG1 and IgG4 antibodies.
    Song Y; Cai H; Tan Z; Mussa N; Li ZJ
    Appl Microbiol Biotechnol; 2022 Feb; 106(3):1057-1066. PubMed ID: 35072737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement.
    Isenman DE; Dorrington KJ; Painter RH
    J Immunol; 1975 Jun; 114(6):1726-9. PubMed ID: 1127227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranking the susceptibility of disulfide bonds in human IgG1 antibodies by reduction, differential alkylation, and LC-MS analysis.
    Liu H; Chumsae C; Gaza-Bulseco G; Hurkmans K; Radziejewski CH
    Anal Chem; 2010 Jun; 82(12):5219-26. PubMed ID: 20491447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
    Gillies SD; Wesolowski JS
    Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.
    Peters SJ; Smales CM; Henry AJ; Stephens PE; West S; Humphreys DP
    J Biol Chem; 2012 Jul; 287(29):24525-33. PubMed ID: 22610095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of heavy and light chain assembly by modification of heavy chain constant region 1 (CH1): Application for the construction of an anti-paclitaxel fragment antigen-binding (Fab) antibody.
    Yusakul G; Sakamoto S; Tanaka H; Morimoto S
    J Biotechnol; 2018 Dec; 288():41-47. PubMed ID: 30389640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular-mechanics study of the conformation of the interchain disulfide of human immunoglobulin G4 (IgG4).
    Snow ME; Amzel LM
    Mol Immunol; 1988 Oct; 25(10):1019-24. PubMed ID: 3146023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential reduction of the inter-chain disulfide bonds of rat immunoglobulin E: relation to biological activity.
    Rousseaux-Prévost R; Rousseaux J; Bazin H; Biserte G
    Mol Immunol; 1984 Mar; 21(3):233-41. PubMed ID: 6201733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.